Fresh Equities
Offers
Learn
BARD1 LIFE SCIENCES LIMITED

INVESTOR PRESENTATION - BARD1 LIFE SCIENCES LIMITED

ASX:BD1

BARD1 LIFE SCIENCES LIMITED

Health Care

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

Read more

Market Cap

67.05m

Price at Close

$0.028

4w avg. Volume

3.03m

4w avg. Turnover

$86.69k

Announcements
announcementt+2 movementdate
  • BARD1 Awarded BTB Funding to Develop Breast Cancer Test

    Progress Report · Market sensitive

  • 0.00%

    02 Sep 2020

0.00%

02 Sep 2020
  • Revised Securities Trading Policy

    Other

  • -3.45%

    31 Aug 2020

-3.45%

31 Aug 2020
  • Appendix 4G and Corporate Governance Statement

    Periodic Reports

  • -6.67%

    24 Aug 2020

-6.67%

24 Aug 2020
  • Appendix 4E and Annual Report to Shareholders

    Periodic Reports · Market sensitive

  • -6.67%

    24 Aug 2020

-6.67%

24 Aug 2020
  • Change of Director's Interest - Helen Fisher

    Shareholder Details

  • -6.67%

    24 Aug 2020

-6.67%

24 Aug 2020
  • Change of Director's Interest - Dr Geoffrey Cumming

    Shareholder Details

  • -6.67%

    24 Aug 2020

-6.67%

24 Aug 2020
  • European Patent Validated

    Progress Report · Market sensitive

  • -5.71%

    09 Aug 2020

-5.71%

09 Aug 2020
  • Change in substantial holding

    Shareholder Details

  • +9.68%

    04 Aug 2020

+9.68%

04 Aug 2020
  • Initial Director's Interest Notice - Fisher

    Shareholder Details

  • +9.68%

    04 Aug 2020

+9.68%

04 Aug 2020
  • Initial Director's Interest Notice - Cumming

    Shareholder Details

  • +9.68%

    04 Aug 2020

+9.68%

04 Aug 2020
Market Data

Current Price

$0.028

52WK HIGH

$0.056

52WK LOW

$0.019

1YR RETURN

-17.65%

1YR RETURN VS. SECTOR

-33.89%

90 DAY RETURN

-3.45%

ASX RANK

911

/2,019

SECTOR RANK

7

/14

SHARES OUTSTANDING

2.39b
ASX:BD1

BARD1 LIFE SCIENCES LIMITED

Health Care

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

Read more

Market Cap

67.05m

Price at Close

$0.028

4w avg. Volume

3.03m

4w avg. Turnover

$86.69k

ASX:BD1 is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Ask Fresh

Archive
Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.